Search

Thiethylperazine

A dopamine antagonist that is particularly useful in treating the nausea and vomiting associated with anesthesia, mildly emetic cancer chemotherapy agents, radiation therapy, and toxins.

Onasemnogene abeparvovec

Developed by AveXis, a Novartis company,[A187253] onasemnogene abeparvovec is commonly marketed as Zolgensma®, which is available as a single-dose intravenous infusion. … muscular atrophy (SMA) and a specific mutation in the survival motor neuron 1 (SMN1) gene.

Bebtelovimab

Bebtelovimab (LY-COV1404, LY-3853113) is a human monoclonal antibody approved for emergency use in the treatment of COVID-19. … [L40328] Bebtelovimab was issued an emergency use authorization (EUA) by the FDA on February 11, 2022, for the treatment of mild-to-moderate COVID-19 in select patients.

Daclizumab

This withdrawal was concurrent to the European Medicines Agency announcement of a recall owing to 12 worldwide reports of serious inflammatory brain disorders associated with the use of Zinbryta (daclizumab … Despite being approved for use, Zinbryta (daclizumab)'s complex pre-existing safety profile consisting of its restricted availability through a Risk Evaluation and Mitigation Strategy program [L1738] and

Methyl-D9-choline

Methyl-D9-choline is under investigation in clinical trial NCT01807910 (ER Stress in NAFLD).

EA-2353

EA-2353 is a small molecule inhibitor of kinase mediators of the Wnt pathway.

Lecithin, soybean

A complex mixture of phospholipids; glycolipids; and triglycerides; with substantial amounts of phosphatidylcholines; phosphatidylethanolamines; and phosphatidylinositols, which are sometimes loosely termed … Lecithin is a component of the cell membrane and commercially extracted from soybeans and egg yolk.

APT20TTMG

APT20TTMG is a synthetic DNA that modulates U1 small nuclear ribonucleoprotein misassembly.

Potassium triiodide

Revefenacin

The LAMA group falls into a parent category known as long-acting inhaled bronchodilators and this type of agents are recommended as a maintenance therapy for chronic obstructive pulmonary disease (COPD … [A40026] It was developed by Theravance Biopharma and FDA approved on November 9, 2018.[L4818]